International Journal of Pharma Insight Studies

Real-World Evidence (RWE) in Drug Development: Regulatory and Clinical Utility

Emily Zhang
Faculty of Business, University of British Columbia, Canada

* Corresponding Author: **Emily Zhang**

Article Info

Volume: 02
Issue: 03
May-June 2025
Received: 09-03-2025
Accepted: 13-04-2025
Page No: 10-12

Abstract
Real-World Evidence (RWE) has emerged as a critical pillar in modern drug development, playing a pivotal role in regulatory submissions, post-marketing surveillance, and clinical decision-making. Derived from Real-World Data (RWD), including electronic health records, claims data, patient registries, and wearable devices, RWE provides insights into the safety, efficacy, and value of medical interventions in real-life clinical settings. This article explores the growing integration of RWE in drug development, emphasizing its regulatory acceptance and clinical relevance. We review methodological frameworks, case studies, and the evolving regulatory landscape led by the US FDA and the European Medicines Agency (EMA). The paper also discusses the strengths, limitations, and future prospects of RWE, arguing for its broader incorporation alongside randomized controlled trials (RCTs). Findings suggest that when rigorously designed and transparently reported, RWE studies can complement traditional clinical trials and significantly enhance patient-centered healthcare innovation.

Keywords: Real-World Evidence, Real-World Data, Drug Development, Regulatory Science, FDA, EMA, Post-Marketing Surveillance, Observational Studies, Pharmacoepidemiology, Clinical Utility

1. Introduction

The drug development paradigm has long been dominated by randomized controlled trials (RCTs), revered for their internal validity and regulatory robustness. However, RCTs often fall short in representing real-world patient populations, healthcare settings, and long-term outcomes. In response to these limitations, Real-World Evidence (RWE) has garnered increasing interest from regulators, payers, healthcare providers, and pharmaceutical companies.

RWE is derived from Real-World Data (RWD) — data collected outside traditional clinical trials. This includes electronic health records (EHRs), claims and billing activities, product and disease registries, mobile health apps, and social media. These data sources capture a broader and more diverse patient population, offering valuable insights into drug performance in routine clinical practice.

Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are now incorporating RWE into regulatory decision-making processes. Furthermore, RWE plays a crucial role in pharmacovigilance, health technology assessments (HTAs), label expansions, and comparative effectiveness research.

This article aims to explore the multifaceted role of RWE in drug development, highlight regulatory and clinical applications, discuss methodological considerations, and outline the challenges and future directions of this evolving landscape.

2. Materials and Methods

2.1 Literature Review

We conducted a systematic literature review using databases including PubMed, Scopus, and Embase. Search terms included "Real-World Evidence", "Real-World Data", "regulatory decision-making", "drug development", and "observational studies". Peer-reviewed articles, guidelines, and white papers from 2015–2024 were included.

2.2 Regulatory Document Analysis

We analyzed regulatory documents, frameworks, and guidelines from:

- U.S. FDA (e.g., Framework for RWE Program, 2018)
- EMA (e.g., EMA Reflection Paper on RWE, 2021)

- Health Canada and PMDA Japan Focus was placed on the use of RWE in approval pathways and post-market safety evaluation.

2.3. Case Studies
Four case studies were selected based on their use of RWE in regulatory approval or clinical decision-making:
- Pfizer's Ibrance label expansion
- Novartis' Kymriah post-marketing studies
- Use of RWE for COVID-19 treatment evaluation
- Flatiron Health data used in oncology submissions

Each case was analyzed for data source, methodology, and regulatory outcome.

2.4. Methodological Evaluation
We compared different observational designs:
- Cohort studies
- Case-control studies
- Pragmatic trials Statistical techniques, including propensity score matching and sensitivity analyses, were evaluated for bias reduction and validity enhancement.

3. Results
3.1 Growth in RWE-Based Submissions
Between 2017 and 2023, FDA received over 120 regulatory submissions containing RWE components. A 2022 report revealed that 65% of new drug applications (NDAs) and supplemental NDAs contained some form of RWE.

3.2 Regulatory Acceptance
- **FDA**: Approved the label expansion of *Ibrance (palbociclib)* based on a Flatiron Health real-world cohort, demonstrating consistency with previous RCTs.
- **EMA**: Accepted RWE in HTA assessments and rare disease treatments, especially where RCTs are unfeasible.

3.3 Case Study Highlights
Case 1: Pfizer's Ibrance
- **Data Source**: Flatiron EHR
- **Outcome**: Label expansion for male breast cancer
- **Impact**: FDA accepted RWE in lieu of traditional trial due to rarity of condition

Case 2: COVID-19 Treatment Evaluation
- **Data Source**: National COVID Cohort Collaborative (N3C)
- **Methods**: Rapid analysis using matched cohorts
- **Impact**: Guided therapeutic guidelines before large RCTs completed

Case 3: Novartis' Kymriah
- **Data Source**: Registry and post-marketing surveillance
- **Outcome**: Informed risk mitigation strategies
- **Impact**: Supported EMA's conditional approval continuation

3.4 RWE in Clinical Practice
RWE has enabled:
- Identification of off-label drug benefits
- Detection of rare adverse events
- Comparative effectiveness studies across populations
- Real-time pharmacovigilance

4. Discussion
4.1 Advantages of RWE
- **Generalisability**: Includes diverse populations often excluded from RCTs (elderly, comorbidities)
- **Speed and Cost-Effectiveness**: RWE can be gathered faster and at lower cost
- **Post-Marketing Insights**: Crucial for long-term safety and effectiveness data
- **Support for Rare Diseases**: Where traditional RCTs are impractical due to low patient numbers

4.2 Regulatory Utility
Regulatory bodies are actively embracing RWE:
- FDA's RWE Framework emphasizes rigorous design and data quality
- EMA's DARWIN EU initiative facilitates federated data access
- Japan's PMDA allows RWE in oncology and rare disease contexts

4.3 Methodological Rigor
Observational studies require:
- Careful design to avoid bias
- Advanced statistical techniques like propensity scoring
- Transparent reporting and validation
- Alignment with STaRT-RWE and ISPE/ISPOR good practice guidelines

4.4 Challenges and Limitations
- **Data Quality and Standardization**: Fragmented EHRs, incomplete datasets
- **Confounding and Bias**: Selection bias, indication bias, measurement errors
- **Regulatory Skepticism**: Need for reproducibility and traceability
- **Ethical and Privacy Concerns**: GDPR and HIPAA compliance is mandatory

4.5 Future Directions
- Integration of AI/ML for signal detection and predictive analytics
- Enhanced data linkage across sources (EHRs + claims + genomics)
- Use in decentralized trials and adaptive designs
- Development of global RWE governance standards

5. Conclusion
RWE has transitioned from a supplementary data source to a mainstream component in drug development and regulation. It offers valuable real-world insights that enhance clinical relevance, especially when traditional trials are limited. Regulatory agencies are increasingly integrating RWE into approval and surveillance frameworks, provided methodological and ethical standards are met.

Future efforts should focus on improving data quality, analytical rigor, and transparency. As health systems become more digitized and interoperable, RWE will likely play an even greater role in accelerating access to effective and safe

therapies across diverse patient populations.

References

1. U.S. Food and Drug Administration. Framework for FDA's Real-World Evidence Program. 2018.
2. Sherman RE, Anderson SA, Dal Pan GJ, *et al*. *Real-world evidence — what is it and what can it tell us?* N Engl J Med. 2016;375(23):2293–2297.
3. European Medicines Agency. EMA Regulatory Science Strategy to 2025. EMA; 2020.
4. Makady A, de Boer A, Hillege H, *et al*. *What is real-world data? A review of definitions based on literature and stakeholder interviews*. Value Health. 2017;20(7):858–865.
5. Corrigan-Curay J, Sacks L, Woodcock J. *Real-world evidence and real-world data for evaluating drug safety and effectiveness*. JAMA. 2018;320(9):867–868.
6. FDA. Real-World Evidence. [Internet]. 2024 [cited 2025 May 1]. Available from: https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence
7. Schneeweiss S. *Learning from big health care data*. N Engl J Med. 2014;370(23):2161–2163.
8. Garrison LP, Neumann PJ, Erickson P, Marshall D, Mullins CD. *Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report*. Value Health. 2007;10(5):326–335.
9. Khozin S, Blumenthal GM, Pazdur R. *Real-world data for clinical evidence generation in oncology*. J Natl Cancer Inst. 2017;109(11):djx187.
10. Eichler HG, Bloechl-Daum B, Abadie E, Barnett D, Konig F, Pearson S. *Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers*. Nat Rev Drug Discov. 2010;9(4):277–291.
11. Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. *Real-world data in diabetes management*. Clin Diabetes. 2018;36(2):152–162.
12. FDA. Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices: Guidance for Industry. 2017.
13. Dreyer NA, Mack CD, O'Neill RT, *et al*. *Use of real-world evidence in regulatory decision making — opportunities and challenges*. Clin Pharmacol Ther. 2016;100(6):594–597.
14. Franklin JM, Schneeweiss S. *When and how can real-world data analyses substitute for randomized controlled trials?* Clin Pharmacol Ther. 2017;102(6):924–933.
15. Booth CM, Karim S, Mackillop WJ. *Real-world data: towards achieving the achievable in cancer care*. Nat Rev Clin Oncol. 2019;16(5):312–325.
16. Casey JA, Schwartz BS, Stewart WF, Adler NE. *Using electronic health records for population health research: a review of methods and applications*. Annu Rev Public Health. 2016;37:61–81.
17. Angelis A, Lange A, Kanavos P. *Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries*. Eur J Health Econ. 2018;19(1):123–152.
18. Mayer MA, Rodríguez-González A, Muñoz-Cuevas JF. *Using real-world evidence for drug approvals in rare diseases: current challenges and solutions*. Orphanet J Rare Dis. 2021;16(1):1–12.
19. Makady A, van Veelen A, Jonsson P, *et al*. *Using real-world data in health technology assessment (HTA) practice: a comparative study of five HTA agencies*. Pharmacoeconomics. 2018;36(3):359–368.
20. EMA. Use of Real-World Evidence in Medicines Regulation. EMA Reflection Paper. 2021.
21. Flatiron Health. Real-world evidence for oncology innovation. [Internet]. 2023.
22. Fleurence RL, Curtis LH, Califf RM, Platt R, Selby JV, Brown JS. *Launching PCORnet, a national patient-centered clinical research network*. J Am Med Inform Assoc. 2014;21(4):578–582.
23. Liu J, Huang J, Zhao Y, *et al*. *Real-world effectiveness of COVID-19 treatments: lessons learned*. J Clin Invest. 2022;132(3):e154949.
24. PMDA Japan. Real-World Data Use in Regulatory Submissions. Tokyo: Pharmaceuticals and Medical Devices Agency; 2022.
25. Khosla S, White R, Medina J, *et al*. *Real-world evidence: a global perspective*. Ther Innov Regul Sci. 2018;52(3):336–341.
26. ISPOR/ISPE. Good Practices for Real-World Data Studies. 2020.
27. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. *High-dimensional propensity score adjustment in studies of treatment effects using health care claims data*. Epidemiology. 2009;20(4):512–522.